IGFBP2 and central nervous system cancer: Likewise, Phillip and collaborators (2016) further reported that deficient-IGFBP2 glioma cell treatment with IGFBP2 resulted in a rapid increase of lysine-specific demethylase 1 (LSD1) and methylated histones that have been identified as direct targets of LSD1 (H3K9 and H3K27).